NEKTAR THERAPEUTICS
For the period ended Dec 31, 2025. Filed Mar 13, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 13, 2026
NKTR$37.78-0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at December 31, 2025 and 2024
CONSOLIDATED BALANCE SHEETS
| December 31, | ||||
|---|---|---|---|---|
| 2025 | 2024(1) | |||
| ASSETS | ||||
| Current assets: | ||||
| Cash and cash equivalents | $15,116 | $44,252 | ||
| Short-term investments | 230,636 | 210,974 | ||
| Other current assets (including $429 and $0 as of December 31, 2025 and 2024, respectively, from a related party) | 20,514 | 6,066 | ||
| Total current assets | 266,266 | 261,292 | ||
| Long-term investments | — | 13,869 | ||
| Property, plant and equipment, net | 2,060 | 3,411 | ||
| Operating lease right-of-use assets | 2,941 | 8,413 | ||
| Equity method investment in Gannet BioChem | 3,491 | 12,218 | ||
| Other assets | 5,648 | 4,647 | ||
| Total assets | $280,406 | $303,850 | ||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||
| Current liabilities: | ||||
| Accounts payable (including $137 and $0 as of December 31, 2025 and 2024, respectively, to a related party) | $10,770 | $11,560 | ||
| Accrued expenses (including $994 and $3,403 as of December 31, 2025 and 2024, respectively, to a related party) | 22,271 | 29,972 | ||
| Operating lease liabilities, current portion | 20,495 | 19,868 | ||
| Total current liabilities | 53,536 | 61,400 | ||
| Operating lease liabilities, less current portion | 65,256 | 82,696 | ||
| Liabilities related to the sales of future royalties, net | 63,157 | 91,776 | ||
| Other long-term liabilities | 8,625 | 7,241 | ||
| Total liabilities | 190,574 | 243,113 | ||
| Commitments and contingencies | ||||
| Stockholders’ equity: | ||||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares designated or outstanding at December 31, 2025 or 2024, respectively | — | — | ||
| Common stock, $0.0001 par value; 390,000,000 shares and 300,000,000 shares authorized at December 31, 2025 and 2024, respectively; 20,378,832 shares and 12,937,308 shares issued at December 31, 2025 and 2024, respectively; 20,378,832 shares and 12,385,001 shares outstanding at December 31, 2025 and 2024, respectively | 2 | 1 | ||
| Capital in excess of par value | 3,850,099 | 3,659,885 | ||
| Treasury stock, at cost; 0 shares and 552,307 shares as of December 31, 2025 and 2024, respectively | — | (3,000) | ||
| Accumulated other comprehensive income (loss) | 17 | 61 | ||
| Accumulated deficit | (3,760,286) | (3,596,210) | ||
| Total stockholders’ equity | 89,832 | 60,737 | ||
| Total liabilities and stockholders’ equity | $280,406 | $303,850 | ||
(1)All share and per share amounts have been retrospectively adjusted to reflect aone-for-fifteen reverse stock split (see Note 8).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.